US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maze Therapeutics

14.75

-0.7500-4.84%

Pre-market: 15.000.2500+1.69%08:00 EDT

Volume:270.21K

Turnover:4.04M

Market Cap:646.01M

PE:43.97

High:15.68

Open:15.13

Low:14.20

Close:15.50

Loading ...

Overview Company News Filings

Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027

Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year

Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Maze Therapeutics receives positive ratings following recent IPO

BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period

TD Cowen Initiates Maze Therapeutics at Buy

MT Newswires Live

Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target

MT Newswires Live

Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target

MT Newswires Live

JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target

MT Newswires Live

Maze Therapeutics Initiated at Overweight by JP Morgan

Maze Therapeutics initiated with a Buy at TD Cowen

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829

Maze Therapeutics initiated with an Overweight at JPMorgan

Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market

Maze Therapeutics initiated with a Buy at Guggenheim

Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Stock Track | Maze Therapeutics Soars 6.25% After Pricing Upsized $140 Million IPO at $16 Per Share

Oil company Infinity Natural Resources debuts IPO amid deregulation push

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MAZE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":14.75,"timestamp":1753992000000,"preClose":15.5,"halted":0,"volume":270205,"hourTrading":{"tag":"盘前","latestPrice":15,"preClose":14.75,"latestTime":"08:00 EDT","volume":41,"amount":616.750003,"timestamp":1754049601130},"delay":0,"floatShares":16929527,"shares":43797166,"eps":0.33546,"marketStatus":"Pre-Mkt","change":-0.75,"latestTime":"08-01 08:12:29 EDT","open":15.13,"high":15.68,"low":14.2,"amount":4035522.2129949997,"amplitude":0.095484,"askPrice":15.35,"askSize":21,"bidPrice":10.06,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.33546,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754055000000},"marketStatusCode":1,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":14.75,"preHourTrading":{"tag":"盘前","latestPrice":15,"preClose":14.75,"latestTime":"08:00 EDT","volume":41,"amount":616.750003,"timestamp":1754049601130},"postHourTrading":{"tag":"盘后","latestPrice":15.05,"preClose":14.75,"latestTime":"19:55 EDT","volume":1228,"amount":18171.55,"timestamp":1754006125993},"volumeRatio":3.2474767051316653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":16929527,"roa":"11.44%","roe":"34.38%","lyrEps":1.421062,"volumeRatio":3.2474767051316653,"shares":43797166,"dividePrice":0,"high":15.68,"amplitude":0.095484,"preClose":15.5,"low":14.2,"week52Low":6.71,"pbRate":"2.21","psRate":"3.86","week52High":19.19,"institutionHeld":0,"latestPrice":14.75,"committee":0.652893,"eps":0.33546,"divideRate":0,"volume":270205,"delay":0,"ttmEps":0.33546,"open":15.13,"prevYearClose":16,"prevWeekClose":16.82,"prevMonthClose":14.75,"prevQuarterClose":12.27,"fiveDayClose":16.45,"twentyDayClose":11.86,"sixtyDayClose":10.42},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523948901","title":"Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948901","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948901?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:39","pubTimestamp":1743421182,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44559054/maze-therapeutics-q4-2024-gaap-eps-18-32-vs-11-46-yoy-raised-140m-in-gross-proceeds-in-upsized-ip","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2523594338","title":"Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2523594338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523594338?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743420986,"startTime":"0","endTime":"0","summary":"“Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with two ongoing clinical-stage programs – MZE829 for AKD a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q4-eps-18-32-vs-11-46-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q4-eps-18-32-vs-11-46-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2523948396","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948396?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease ; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025. Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., March 31, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, highlighted recent progress and reiterated upcoming milestones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4007","MAZE"],"gpt_icon":0},{"id":"2514704435","title":"Maze Therapeutics receives positive ratings following recent IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704435","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704435?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:11","pubTimestamp":1740517867,"startTime":"0","endTime":"0","summary":"Investing.com -- Maze Therapeutics Inc received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.Maze's lead drug candidate, MZE829, is an oral APOL1 inhibitor being developed for APOL1-mediated kidney disease. Analysts expect key Phase II HORIZON trial data in early 2026, with TD Cowen highlighting its potential to address over 1 million AKD patients and noting its potency advantage over Vertex's  inaxaplin. Guggenheim sees Maze as a compelling investment, given the estimated $10 billion to $15 billion market opportunity in APOL1-associated kidney disease.Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it as a first-in-class therapy with significant commercial potential.JPMorgan, which set a $30 price target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maze-therapeutics-receives-positive-ratings-211107907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAZE"],"gpt_icon":0},{"id":"2514968019","title":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period","url":"https://stock-news.laohu8.com/highlight/detail?id=2514968019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514968019?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:13","pubTimestamp":1740499987,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34 ** Wall Street brokerages start coverage of the drug de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG1OA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4211","MAZE","BK4007","BK4207","SIVBQ","BK4585","BK4589"],"gpt_icon":0},{"id":"2514067325","title":"TD Cowen Initiates Maze Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067325","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067325?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:22","pubTimestamp":1740482522,"startTime":"0","endTime":"0","summary":"TD Cowen Initiates Maze Therapeutics at Buy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MAZE","BK4566","COWN","TD","BK4585","BK4127","BK4207"],"gpt_icon":0},{"id":"2514067327","title":"Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067327?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482514,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514067340","title":"Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067340?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482507,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514067373","title":"JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067373?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482493,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514199064","title":"Maze Therapeutics Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514199064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514199064?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:49","pubTimestamp":1740480540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 05:49 ET (10:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2514064852","title":"Maze Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064852?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:41","pubTimestamp":1740480066,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, could...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4207","BK4566","BK4127","COWN","TD","MAZE","BK4007"],"gpt_icon":0},{"id":"2514064866","title":"Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064866?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:35","pubTimestamp":1740479737,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler Van Buren has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-drug-candidates-and-market-potential-drive-buy-rating-for-maze-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-drug-candidates-and-market-potential-drive-buy-rating-for-maze-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514690200","title":"Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829","url":"https://stock-news.laohu8.com/highlight/detail?id=2514690200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514690200?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:15","pubTimestamp":1740478550,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by J.P. Morgan analyst, Anupam Rama. Anupam Rama has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-backed-by-promising-pipeline-and-lead-asset-mze829?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-backed-by-promising-pipeline-and-lead-asset-mze829?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514069091","title":"Maze Therapeutics initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514069091?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:11","pubTimestamp":1740478271,"startTime":"0","endTime":"0","summary":"JPMorgan initiated coverage of Maze Therapeutics (MAZE) with an Overweight rating and $30 price target The company’s Compass platform has produced ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514069076","title":"Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514069076?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:08","pubTimestamp":1740478092,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by Guggenheim analyst, Debjit Chattopadhyay. Debjit Chattopadhyay has given...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-strategic-positioning-and-growth-potential-in-genetic-disorders-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-strategic-positioning-and-growth-potential-in-genetic-disorders-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2514660070","title":"Maze Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2514660070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514660070?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:01","pubTimestamp":1740477705,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $19 price target The company has advan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2508099804","title":"Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2508099804","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508099804?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:38","pubTimestamp":1738345112,"startTime":"0","endTime":"0","summary":"UPDATE 3-Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debutAdds analyst comments in paragraph 11By Ateev Bhandari","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR1C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0173614495.USD","LU0274383008.USD","BK1543","BK1521","BK4023","SG9999001051.SGD","LU0287142896.SGD","BK1603","LU0541502299.USD","LU1166156734.SGD","SG9999001069.SGD","LU0702159699.USD","BK1237","LU0541501648.USD","00288","SG9999002950.SGD","SFD","SGXZ90724238.SGD","VG","MAZE","SG9999001226.SGD"],"gpt_icon":0},{"id":"2508998165","title":"Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2508998165","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508998165?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:25","pubTimestamp":1738344329,"startTime":"0","endTime":"0","summary":"Maze Therapeutics valued at $690.4 million as shares rise marginally in market debutJan 31  - Shares of Maze Therapeutics MAZE.O rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR1BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"1136600250","title":"Stock Track | Maze Therapeutics Soars 6.25% After Pricing Upsized $140 Million IPO at $16 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1136600250","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136600250?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:22","pubTimestamp":1738344145,"startTime":"0","endTime":"0","summary":"Shares of Maze Therapeutics  surged 6.25% in Friday's trading session, following the company's successful pricing of its upsized initial public offering  a day earlier.On Thursday evening, Maze Therapeutics announced that it had priced its IPO of approximately 8.8 million shares at $16 per share, raising gross proceeds of $140 million. The offering was upsized from the company's initial plans, indicating strong investor demand.In addition to the 8.8 million shares sold in the IPO, Maze Therapeut","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Maze Therapeutics Soars 6.25% After Pricing Upsized $140 Million IPO at $16 Per Share","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MAZE"],"gpt_icon":0},{"id":"2507961888","title":"Oil company Infinity Natural Resources debuts IPO amid deregulation push","url":"https://stock-news.laohu8.com/highlight/detail?id=2507961888","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507961888?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:20","pubTimestamp":1738336800,"startTime":"0","endTime":"0","summary":"Company prices above midrange as the largest of a batch of initial public offerings on Friday. Infinity Natural Resources Inc. priced its initial public offering above the midpoint of its range in a sign of a strong stock-market debut for the oil and gas producer, which operates in Ohio and Pennsylvania.The IPO comes amid a deregulatory push in the energy sector by President Donald Trump, who repeated the \"drill, baby, drill\" slogan in his inaugural address.Earlier this week, Sean Duffy, the newly sworn-in Transportation secretary, ordered a review of fuel-economy standards laid out by the Biden administration.Infinity Natural Resources  priced 13.25 million shares at $20 for proceeds of $265 million. The IPO priced toward the upper end of its range of $18 to $21 in a sign of healthy demand.Infinity Natural Resources is the largest of a handful of IPOs on Friday.Maze Therapeutics Inc.  priced 8.75 million shares at $16 a share for proceeds of $140 million. The stock priced at the midpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","INR","MTSR","BBNX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1753329600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2025-07-31","current":13.070257,"percent":0.896,"low":6.347498,"twenty":8.267679,"median":9.46183,"eighty":11.248853,"high":14.99285,"avg":9.777028,"sd":2.024561,"marketCap":678856073},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-07-31","current":13.070257,"twenty":8.267679,"median":9.46183,"eighty":11.248853,"marketCap":678856073}],"updateTime":1754050349668}}}